In August 2020, IQVIA published results of an analysis1 of the size and growth of the 340B Drug Discount Program ("340B Program"), showing it had grown 17.1% year-on-year in 2019 and accounted for $67.4B of pharma sales (dollarized using WAC pricing). READ MORE